CA3168980A1 - Compositions and methods for treating cancer and tumor - Google Patents

Compositions and methods for treating cancer and tumor Download PDF

Info

Publication number
CA3168980A1
CA3168980A1 CA3168980A CA3168980A CA3168980A1 CA 3168980 A1 CA3168980 A1 CA 3168980A1 CA 3168980 A CA3168980 A CA 3168980A CA 3168980 A CA3168980 A CA 3168980A CA 3168980 A1 CA3168980 A1 CA 3168980A1
Authority
CA
Canada
Prior art keywords
day
body weight
tumor
cancer
effective amount
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
CA3168980A
Other languages
English (en)
French (fr)
Inventor
Sin Wook Kang
Kyeongsoon KIM
Ji Hye SUNG
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Oblato Inc
Original Assignee
Oblato Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Oblato Inc filed Critical Oblato Inc
Publication of CA3168980A1 publication Critical patent/CA3168980A1/en
Pending legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/16—Otologicals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/04—Antineoplastic agents specific for metastasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner

Landscapes

  • Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Epidemiology (AREA)
  • Oncology (AREA)
  • Engineering & Computer Science (AREA)
  • Hematology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
CA3168980A 2020-02-24 2021-02-24 Compositions and methods for treating cancer and tumor Pending CA3168980A1 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US202062980645P 2020-02-24 2020-02-24
US62/980,645 2020-02-24
PCT/US2021/019457 WO2021173702A1 (en) 2020-02-24 2021-02-24 Compositions and methods for treating cancer and tumor

Publications (1)

Publication Number Publication Date
CA3168980A1 true CA3168980A1 (en) 2021-09-02

Family

ID=77490220

Family Applications (1)

Application Number Title Priority Date Filing Date
CA3168980A Pending CA3168980A1 (en) 2020-02-24 2021-02-24 Compositions and methods for treating cancer and tumor

Country Status (8)

Country Link
US (1) US20230092005A1 (enExample)
EP (1) EP4110315A4 (enExample)
JP (1) JP2023514742A (enExample)
KR (1) KR20220145861A (enExample)
CN (1) CN115151250A (enExample)
AU (1) AU2021228654A1 (enExample)
CA (1) CA3168980A1 (enExample)
WO (1) WO2021173702A1 (enExample)

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5488145A (en) * 1993-12-23 1996-01-30 Oklahoma Medical Research Foundation 2,4-disulfonyl phenyl butyl nitrone, its salts, and their use as pharmaceutical free radical traps
WO2009102808A2 (en) * 2008-02-12 2009-08-20 Tosk, Incorporated Doxorubicin adjuvants to reduce toxicity and methods for using the same
AU2009288057B2 (en) * 2008-09-02 2014-07-03 Oklahoma Medical Research Foundation 2, 4-disulfonyl pheny tert-butyl nitrone for the treatment of gliomas
WO2012106313A2 (en) * 2011-01-31 2012-08-09 Oklahoma Medical Research Foundation Ubiquitin interacting motif peptides as cancer therapeutics
EP3570826A4 (en) * 2017-01-19 2020-09-23 Otologic Pharmaceutics, Inc. N-ACETYLCYSTEIN FORMULATIONS AND THEIR USES
KR101905864B1 (ko) * 2017-03-20 2018-10-08 아주대학교산학협력단 Sulf2 유전자를 이용한 소라페닙 치료에 대한 감수성 예측방법 및 sulf2 저해제를 포함하는 암 치료용 조성물
ES3063479T3 (en) * 2017-09-20 2026-04-16 Oklahoma Med Res Found Treatment of drug resistant gliomas
EP3787750A1 (en) * 2018-05-03 2021-03-10 Hough Ear Institute Methods for reducing accumulated pathologic tau protein

Also Published As

Publication number Publication date
CN115151250A (zh) 2022-10-04
US20230092005A1 (en) 2023-03-23
KR20220145861A (ko) 2022-10-31
WO2021173702A1 (en) 2021-09-02
JP2023514742A (ja) 2023-04-07
EP4110315A1 (en) 2023-01-04
AU2021228654A1 (en) 2022-10-13
EP4110315A4 (en) 2024-03-06
WO2021173702A8 (en) 2022-08-18

Similar Documents

Publication Publication Date Title
US20230093147A1 (en) Methods and compositions relating to improved combination therapies
US12059397B2 (en) Calcium lactate compositions and methods of use
JP2020505433A (ja) Ｈｓｐ９０阻害剤を使用してがんを治療するための方法
CN112218658A (zh) 热量限制模拟物用于增强癌症治疗的化学免疫疗法的用途
JP7579636B2 (ja) 膵がん治療のための組み合わせ治療薬
US10905661B2 (en) Disulfiram and metal salt staggered oral dosing regimen and staggered-release oral unit dosage forms
US20240099999A1 (en) Use of colchicine to inhibit tumor growth and metastases
JP2022160654A (ja) 細胞生存性及び／又は細胞増殖を低減するための薬物の組み合わせ
CN118139642A (zh) 治疗癌症的组合物和方法
US20230092005A1 (en) Compositions and methods for treating cancer and tumor
KR20230005185A (ko) 할로겐화 잔텐의 경구 투여에 의한 고형 암성 종양의 치료
US11484591B2 (en) Chemoprevention using controlled-release formulations of anti-interleukin 6 agents, synthetic vitamin A analogues or metabolites, and estradiol metabolites
US20230058726A1 (en) Chemoprevention using controlled- release formulations of anti-interleukin 6 agents, synthetic vitamin a analogues or metabolites, and estradiol metabolites
Zhu et al. Synergistic Activation of Immunogenic Cell Death and the cGAS–STING Pathway by Engineered Zinc/Manganese‐Based Metal–Organic Framework Nanoplatforms for Colon Cancer Immunotherapy
US12064507B2 (en) Composition and method for oral treatment of leukemia
RU2777519C2 (ru) Применение ингибитора parp в лечении резистентного к химиотерапии рака яичников или рака молочной железы
US20210113692A1 (en) Dosing regimen
HK40105345A (zh) 治疗癌症的组合物和方法
EA045002B1 (ru) Применение колхицина для ингибирования роста опухоли и метастазов

Legal Events

Date Code Title Description
W00 Other event occurred

Free format text: ST27 STATUS EVENT CODE: A-1-1-W10-W00-W100 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: LETTER SENT

Effective date: 20250826

U13 Renewal or maintenance fee not paid

Free format text: ST27 STATUS EVENT CODE: N-1-6-U10-U13-U300 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: DEEMED ABANDONED - FAILURE TO RESPOND TO MAINTENANCE FEE NOTICE

Effective date: 20251027

W00 Other event occurred

Free format text: ST27 STATUS EVENT CODE: N-6-6-W10-W00-W100 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: LETTER SENT

Effective date: 20260202

W00 Other event occurred

Free format text: ST27 STATUS EVENT CODE: N-6-6-W10-W00-W100 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: LETTER SENT

Effective date: 20260423